MARKET WIREReuters • 4h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
Why AGMB Stock slipped -0.13% Today — RQD Quant Desk Flash
$7.95 -0.13% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $7.93
AgomAb Therapeutics NV (AGMB) carries a Roarable Rating of D (Sell) with 51/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D • SELL / AVOID
Cap $391.5M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on AGMB Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is AGMB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-01, AgomAb Therapeutics NV (NASDAQ: AGMB) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 51/100 at a spot price of $7.95 (-0.13% 1D, market cap $391.5M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, AGMB ranks #334 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does AGMB compare to FENC and TECX in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), AGMB carries a Roarable D (51/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, FENC (Fennec Pharmaceuticals Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -25.9%, cap $383.6M) and TECX (Tectonic Therapeutic Inc.) posts a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $400.8M). Among the 5-stock peer group, AGMB leads on earnings multiple (N/A) while FENC leads on capital efficiency (-25.9% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for AGMB?
▼
For AgomAb Therapeutics NV (AGMB), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #334 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $7.93 (-0.21%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0.3% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 51/100 (D) historically posted market-perform odds over rolling 90-day windows (-1.3% avg 90D alpha vs SPY • 49.7% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D
JEV AI Jury Split (Battleground)
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D · Rk D+
Each axis scored 0–20
12M PRICE TARGET CONE-3.1% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for AGMB)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (51/100 Composite)
🔍 WHY AGMB SCORES 51/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (25% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (24% of score)
SEC XBRL Trailing 12 Months: 0.3% FCF Margin ($11.0M FCF) & 52% Gross Margin
▼ #1 Drag / Risk Factor: Whale & Options Positioning7/20 pts (-13 pt drag)
Put hedging (50% put share) caps near-term gamma upside (-13 pts vs max)
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C$9.08-8.8% Next Q
59
Q2 (-2Q)Grade C$8.28+9.3% Next Q
56
Q3 (-1Q)Grade C-$9.05-12.2% Next Q
54
CurrentGrade D$7.95-1.3% Hist 90D α
51
Trajectory: C (59) → D (51)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a AGMB Turnaround Squeeze
While AGMB currently carries a cautious 51/100 (D) rating due to Whale & Options Positioning (7/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($10.92) and Max Pain ($8.35) forces dealer call-delta covering toward $18.71.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $AGMB• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “AGMB Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why AGMB Stock slipped -0.13% Today — RQD Quant Desk Flash
AgomAb Therapeutics NV (AGMB) slipped -0.13% to $7.95, trading at 12% of its 52-week range ($6.61 – $17.82). Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 12% of its 52-week range ($6.61 – $17.82) with RSI-14 at 29.2 (OVERSOLD (<32)).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $7.95 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D (Sell) backed by 52% gross margin and $11.0M annual free cash flow.
Live AGMB Headlines & Catalysts
MARKET WIREReuters • 5h ago
Oil slips more than 1% as talks continue on ending Iran war - ReutersOil slips more than 1% as talks continue on ending Iran war Reuters
MARKET WIREReuters • 6h ago
Nine people dead in Learjet crash in south Florida, officials say - ReutersNine people dead in Learjet crash in south Florida, officials say Reuters
MARKET WIREReuters • 8h ago
Iran's IRGC Navy says two tankers 'exploded' after hitting mines in Hormuz - ReutersIran's IRGC Navy says two tankers 'exploded' after hitting mines in Hormuz Reuters
MARKET WIRECNBC • 10h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
MARKET WIRECNBC • 10h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 11h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 13h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring AGMB)
- ✓Walkthrough of AGMB's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
AGMB // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -26.73%▼ DESCENDING CHANNEL
2026-10-30O $7.00H $7.96L $6.61C $7.95VOL 197.8K
RES: $15.48SUP: $6.78SMA50: $10.92SMA200: $12.11
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
AGMB Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on AGMB today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for AGMB. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for AGMB today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (AGMB)
Health Care Rank #334 of 1016
⚔️ FENC vs AGMB Full Matrix →
1. Head-to-Head Health Care Peer Comparison (AGMB vs. FENC, TECX, CCCC, TRXB)
Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, AgomAb Therapeutics NV (AGMB) ranks #334 by composite RQD confidence (51/100, grade D) and #483 by equity capitalization ($391.5M). Within this direct 5-issuer industry benchmark cohort, AGMB leads on earnings valuation at N/A trailing P/E, while FENC leads on capital efficiency and profitability with -25.9% ROIC and — gross margin. AGMB currently leads its immediate peer cohort in composite quantitative strength at 51/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| AGMB
ACTIVE
AgomAb Therapeutics NV | D | 51/100 | — | — | — | -0.13% | $391.5M | Benchmark Subject |
| FENC Fennec Pharmaceuticals Inc. | D- | 36/100 | — | — | -25.9% | +0.74% | $383.6M | /fenc-vs-agmb → |
| TECX Tectonic Therapeutic Inc. | D- | 37/100 | — | — | -35.0% | -0.29% | $400.8M | /tecx-vs-agmb → |
| CCCC C4 Therapeutics Inc. | E | 27/100 | — | — | -35.0% | -2.80% | $406.0M | /cccc-vs-agmb → |
| TRXB TRex Bio Inc. | D | 49/100 | — | — | — | -6.31% | $371.1M | /trxb-vs-agmb → |
2. AGMB Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics
TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOTAgomAb Therapeutics NV (AGMB) operates in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care) with an equity capitalization of $391.5M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.
3. AGMB Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs AGMB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, AgomAb Therapeutics NV (NASDAQ: AGMB) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 51/100 at a spot price of $7.95 (-0.13% 1D, market cap $391.5M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, AGMB ranks #334 in composite RQD confidence.
How does AGMB compare to FENC and TECX in the Health Care sector?
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), AGMB carries a Roarable D (51/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, FENC (Fennec Pharmaceuticals Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -25.9%, cap $383.6M) and TECX (Tectonic Therapeutic Inc.) posts a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $400.8M). Among the 5-stock peer group, AGMB leads on earnings multiple (N/A) while FENC leads on capital efficiency (-25.9% ROIC).
What are the biggest fundamental strengths and SEC risk factors for AGMB?
For AgomAb Therapeutics NV (AGMB), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #334 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is AGMB trading relative to its 50-day, 200-day, and 52-week technical levels?
AGMB last traded at $7.95 (-0.13% on volume of 575,401 shares), positioning the stock -27.20% below its 50-day simple moving average ($10.92) and -34.35% below its 200-day simple moving average ($12.11). Across its 52-week range of $6.61 to $17.82, AGMB sits at the 12.0% percentile with a 14-day RSI of 29.2 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($6.96 to $8.94).
AGMB Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is AGMB stock moving today?
Why AGMB Stock slipped -0.13% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.